Cited by 209Cancer, Lipids, and MetabolismLipid metabolism and biosynthesisSphingolipid Metabolism and Signaling

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Inhibition of Fatty Acid Synthase Attenuates CD44-Associated Signaling and Reduces Metastasis in Colorectal Cancer

Open access

Published version of a preprint

Abstract

Fatty acid synthase (FASN) and ATP-citrate lyase, key enzymes of de novo lipogenesis, are significantly upregulated and activated in many cancers and portend poor prognosis. Even though the role of lipogenesis in providing proliferative and survival advantages to cancer cells has been described, the impact of aberrant activation of lipogenic enzymes on cancer progression remains unknown. In this study, we found that elevated expression of FASN is associated with advanced stages of colorectal cancer (CRC) and liver metastasis, suggesting that it may play a role in progression of CRC to metastatic disease. Targeted inhibition of lipogenic enzymes abolished expression of CD44, a transmembrane protein associated with metastases in several cancers including CRC. In addition, inhibition of lipogenic enzymes and reduced expression of CD44 attenuated the activation of MET, Akt, FAK, and paxillin, which are known to regulate adhesion, migration, and invasion. These changes were consistent with an observed decrease in migration and adhesion of CRC cells in functional assays and with reorganization of actin cytoskeleton upon FASN inhibition. Despite the modest effect of FASN inhibition on tumor growth in xenografts, attenuation of lipogenesis completely abolished establishment of hepatic metastasis and formation of secondary metastasis. Together, our findings suggest that targeting de novo lipogenesis may be a potential treatment strategy for advanced CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-4057

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 209

Metadata

Authors
Zaytseva, Y. Y., Rychahou, P. G., Gulhati, P., Elliott, V. A., Mustain, W. C., O'Connor, K., Morris, A. J., Sunkara, M., Weiss, H. L., Lee, E. Y., & Evers, B. M.
Affiliations
  • University of Kentucky (US)
  • Authors' Affiliations: 1Markey Cancer Center, Departments of 2Surgery and 3Pathology and Laboratory Medicine, 4Division of Cardiovascular Medicine, and 5Gill Heart Institute, University of Kentucky, Lexington, Kentucky
Corresponding author
Evers, B. Mark
Venue
Cancer Research
Published
2012-03-14
Volume
72
Issue
6
Pages
1504-1517
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1997243908
Cited by
208
References
52
Citations by year
2026: 6 · 2025: 17 · 2024: 19 · 2023: 12 · 2022: 17 · 2021: 19 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 8 · 2016: 19 · 2015: 13 · 2014: 22 · 2013: 7 · 2012: 3
FWCI
4.88
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • UKnowledge (University of Kentucky) (submittedVersion)
Funders
  • National Cancer Institute (P20CA150343, R01CA109136, P20CA1530343, T32CA165990)
  • National Institute of General Medical Sciences (GM-50388, R01GM050388)
  • National Center for Research Resources (S10RR026884, S10RR024598, P20RR021954)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Keywords
fatty acid synthase, ATP citrate lyase, de novo lipogenesis, colorectal cancer, liver metastasis, CD44, C-MET signaling, Akt signaling, focal adhesion kinase, paxillin, cell migration, cell adhesion, actin cytoskeleton
MeSH terms
Animals, Humans, Liver Neoplasms, Male, Mice, Nude, Colorectal Neoplasms, Signal Transduction, Down-Regulation, Hyaluronan Receptors, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Lipogenesis, Oncogene Protein v-akt, Mice, Focal Adhesion Kinase 1, Paxillin, Gene Knockdown Techniques, Fatty Acid Synthases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review